ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France
21st October 2014 - 10:22 am
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is proud to announce that the French region of Aquitaine (around Bordeaux) has awarded ImmuPharma’s subsidiary Ureka a non-refundable grant of approx. €400,000 EUR to develop Ureka’s Urelix technology. The Urelix technology is a way to mimic natural peptides having a helical conformation with artificial residues in order to strengthen this conformation and protect it from enzymatic degradation.
ImmuPharma announced recently that one of the first targets for the Urelix technology is GLP-1, a key peptide in diabetes. This grant confirms the key role Ureka is playing in the biotechnology landscape of the Bordeaux region through its collaboration with ImmuPharma’s longstanding and successful research partner, Centre Nationale de la Recherche Scientifique “CNRS” and Bordeaux University’s research team incubator, Institut Europeen de Chimie et Biologie, as well as the credibility of its technologies.
Dr Robert Zimmer, ImmuPharma’s President and Chief Scientific commented: “We are honoured to have received the grant from the Bordeaux region, not only for the financial support but also importantly for the validation of our innovative research efforts in conjunction with our research partners. We look forward to announcing more exciting news on our programmes in the coming months.”